Loading...
Esperion Therapeutics, Inc.
ESPR•NASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$1.51
$0.02(1.34%)
Esperion Therapeutics, Inc. (ESPR) Financial Performance & Income Statement Overview
Review Esperion Therapeutics, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
185.66%
↑ 185.66%
Operating Income Growth
134.97%
↑ 134.97%
Net Income Growth
75.27%
↑ 75.27%
Operating Cash Flow Growth
82.54%
↑ 82.54%
Operating Margin
-15.40%
↓ 15.40%
Gross Margin
65.30%
↑ 65.30%
Net Profit Margin
-59.03%
↓ 59.03%
ROE
40.07%
↑ 40.07%
ROIC
-75.31%
↓ 75.31%
Esperion Therapeutics, Inc. (ESPR) Income Statement & Financial Overview
Review Esperion Therapeutics, Inc.'s (ESPR) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $69.11M | $51.63M | $73.83M | $137.74M |
| Cost of Revenue | $25.63M | $17.29M | $15.62M | $10.07M |
| Gross Profit | $43.48M | $34.35M | $58.22M | $127.66M |
| Gross Profit Ratio | $0.63 | $0.67 | $0.79 | $0.93 |
| R&D Expenses | $10.98M | $10.40M | $11.46M | $13.40M |
| SG&A Expenses | $36.92M | $39.98M | $44.17M | $41.99M |
| Operating Expenses | $47.90M | $50.37M | $55.64M | $65.47M |
| Total Costs & Expenses | $73.53M | $67.66M | $71.25M | $65.47M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $16.42M | $15.08M | $13.72M | $14.02M |
| Depreciation & Amortization | $27000.00 | $26000.00 | $10000.00 | $41000.00 |
| EBITDA | -$4.87M | -$14.42M | -$48.19M | $75.05M |
| EBITDA Ratio | -$0.07 | -$0.28 | -$0.65 | $0.54 |
| Operating Income | -$4.42M | -$16.03M | $2.58M | $72.27M |
| Operating Income Ratio | -$0.06 | -$0.31 | $0.03 | $0.52 |
| Other Income/Expenses (Net) | -$16.90M | -$13.50M | -$64.50M | -$11.25M |
| Income Before Tax | -$21.32M | -$29.52M | -$61.92M | $61.02M |
| Income Before Tax Ratio | -$0.31 | -$0.57 | -$0.84 | $0.44 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | -$41000.00 |
| Net Income | -$21.32M | -$29.52M | -$61.92M | $61.02M |
| Net Income Ratio | -$0.31 | -$0.57 | -$0.84 | $0.44 |
| EPS | -$0.11 | -$0.15 | -$0.33 | $0.36 |
| Diluted EPS | -$0.11 | -$0.15 | -$0.33 | $0.34 |
| Weighted Avg Shares Outstanding | $191.06M | $194.93M | $188.79M | $169.26M |
| Weighted Avg Shares Outstanding (Diluted) | $191.06M | $194.93M | $188.79M | $189.64M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan